Table 1 Characteristics of the enrolled patients in the training and testing sets
Characteristic | Training set (n = 172) | p | Testing set (n = 75) | p | ||
|---|---|---|---|---|---|---|
LNM (n = 55) | Non-LNM (n = 117) | LNM (n = 24) | Non-LNM (n = 51) | |||
Age (mean ± SD) | 0.083 | 0.64 | ||||
Mean | 51.80 | 54.91 | 55.54 | 54.04 | ||
SD | 11.68 | 8.79 | 10.77 | 10.23 | ||
FIGO stage | 0.69 | 0.64 | ||||
I | 25 (45.45%) | 57 (48.72%) | 9 (37.5%) | 22 (43.14%) | ||
II | 30 (54.55%) | 60 (51.28%) | 15 (62.5%) | 29 (56.86%) | ||
Pathological type | 0.95 | 0.086 | ||||
SCC | 46 (83.64%) | 99 (84.61%) | 20 (83.34%) | 43 (84.31%) | ||
AC | 5 (9.09%) | 8 (6.84%) | 2 (8.33%) | 8 (15.69%) | ||
Others | 4 (7.27%) | 10 (8.55%) | 2 (8.33%) | |||
MTD | 0.016 | 0.009 | ||||
≤ 4 cm | 36 (65.45%) | 96 (82.05%) | 15 (62.50%) | 45 (88.24%) | ||
> 4 cm | 19 (34.55%) | 21 (17.95%) | 9 (37.50%) | 6 (11.76%) | ||
LVSI | < 0.001 | 0.01 | ||||
Negative | 27 (49.09%) | 91 (77.78%) | 13 (54.17%) | 42 (82.35%) | ||
Positive | 28 (50.91%) | 26 (22.22%) | 11 (45.83%) | 9 (17.65%) | ||